Global Arbovirus Testing Market to Reach US$1.9 Billion by 2030, Driven by Rising Outbreaks and Vector Expansion

Industry Experts, Inc. unveils a new report, "Global Arbovirus Testing Market - Tests, Viruses & End-users," forecasting that worldwide revenues for arboviral diagnostics will rise from US$1.4 billion in 2024 to nearly US$1.9 billion by 2030, advancing at a steady compound annual growth rate of 5.8 percent over the 2024-2030 period.

Demand for precise, rapid detection of dengue, Zika, chikungunya, yellow fever, West Nile and related pathogens is accelerating as climate change, urbanization and international travel widen the habitat of Aedes and Culex vectors. The World Health Organization logged more than 7.6 million dengue cases and 620 000 chikungunya infections by April 2024, underscoring how swiftly outbreaks can overwhelm health systems. In response, public-health agencies are upgrading laboratory networks and deploying high-throughput PCR, multiplex ELISA and point-of-care kits that deliver actionable results in hours rather than days.

North America commands roughly 43.4% of global testing revenues, buoyed by strong CDC surveillance programs, advanced molecular platforms and rising incidence of West Nile and dengue across the southern United States and Caribbean territories. Asia-Pacific is on track for the fastest growth, expanding 7.6% annually as India, China and Southeast Asian nations scale integrated mosquito-control campaigns and subsidize early-diagnosis initiatives for rural clinics.

By test type, ELISA assays remain the workhorse of routine screening, representing 46.5% of 2024 demand thanks to their affordability, throughput and suitability for sero-surveillance. RT-PCR will be the quickest-rising technique through 2030, growing 6.8% a year as labs adopt multiplex panels that differentiate co-circulating viruses in a single run. Dengue testing continues to dominate by pathogen, accounting for 45.5% of spending, while chikungunya panels are poised for the sharpest upturn as mutations boost viral transmissibility. Public-health laboratories - often the first line of outbreak confirmation - hold the largest end-user share at 36.9%; diagnostic reference labs follow closely and are recording the briskest uptake of high-sensitivity, multi-pathogen platforms.

The report quantifies arbovirus testing market value across North America, Europe, Asia-Pacific, South America and Rest of World, and dissects demand by test type (ELISA, RT-PCR, NAATs and rapid tests), virus type (dengue, chikungunya, Zika, yellow fever, West Nile and others) and end-user setting (hospitals, diagnostic labs, research institutes and public-health laboratories). It provides historical data for 2021-2023, a 2024 base year and forecasts through 2030, expressed in U.S. dollars. Competitive analysis profiles more than ten key companies including Abbott Laboratories, Bio-Rad, DiaSorin, QIAGEN and Thermo Fisher, highlighting recent assay launches, regional capacity expansions and cross-sector collaborations that are reshaping the arboviral diagnostics landscape.

About Industry Experts, Inc.
Industry Experts, Inc. delivers authoritative market-research intelligence that helps strategists, investors and policymakers anticipate opportunity, benchmark performance and mitigate risk. For further details, call +1-320-497-3787 or visit https://industry-experts.com/.